| Stock | Price | 52 Week Range | Marketcap | EPS | Dividend Yield | Chart (24H) | Sector | Employees | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
| $115.82 | 4.36B | 1.20 | 0.35% | Industrials | 10,000 | 6 mins ago | |||
| $96.80 | 70.65B | 6.61 | 4.62% | Financial Services | 55,767 | 6 mins ago | |||
| $112.87 | 9.66B | 3.44 | 3.93% | Real Estate | 297 | 57 seconds ago | |||
| $93.96 | 117.09B | 0.09 | 3.33% | Healthcare | 18,000 | 3 seconds ago | |||
| $86.70 | 17.03B | 7.32 | 3.15% | Communication Services | 75,900 | 1 min ago | |||
 Pfizer, Inc. PFE | $26.67 | 151.11B | 0.75 | 6.53% | Healthcare | 88,000 | 3 seconds ago |
Greetings, savvy investors! Today, we’re diving into an exhilarating topic – top stocks to buy now to capitalize on the current market dynamics. Despite a few high-impact key reversal days, which typically indicate a potential market downturn, there hasn’t been substantial follow-through. This suggests further gains could be on the horizon, especially with institutional investors on the hunt for bargains in a holiday-shortened week. Let’s delve into six stocks that are not only riding the wave of market volatility but are poised to deliver substantial returns.
Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace
Advanced Energy Industries (AEIS)
Overview
Advanced Energy Industries specializes in precision power conversion products essential for industries such as semiconductor manufacturing, data centers, and solar panels.
Investment Appeal
AEIS stands out with its strong earnings growth. S&P estimates predict earnings of $1.01 per share in 2013, increasing to $1.60 in 2014, and reaching $1.82 in 2015. The stock’s breakout from $15 to $20, characterized by sustained accumulation, is a positive technical indicator. Moreover, AEIS is witnessing a powerful breakout pattern with a potential target of $24, making it an enticing investment opportunity. This robust performance amidst a volatile market reflects its inherent strength and investor confidence.
AEIS: Steady Earning Growth, Targeting $24 Amid Technical Breakout!
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Hold | $108.86 | $108.50 | 0.33% | 9 |
| OUTPERFORM | $109.60 | $107.10 | 2.28% | 9 |
Summary of Analyst Outlook
General Trends: Analysts expect growth but are cautious, with price targets indicating modest potential upside.
Earnings Projections: For the current quarter, EPS is forecasted between $0.63 and $0.83.
Price Movements: The stock has shown fluctuations, trading between $90.00 and $130.00 this year.
Bank of Montreal (BMO)
Overview
The Bank of Montreal is the fourth-largest bank in Canada and ranks eighth in North America, offering a wide range of financial services.
Investment Appeal
BMO is a pillar of stability with a dividend yield of 4.8%. The stock’s support around $60, coupled with a recent Moving Average Convergence Divergence (MACD) buy signal, enhances its appeal. BMO‘s bullish support line suggests a potential target of $68, translating to an impressive annual return of over 15%. For those looking for a blend of growth and income, BMO is a strong contender, providing a cushion amidst market fluctuations.
BMO: Targeting a Strong Annual Return of Over 15% with Bullish Momentum
| Consensus Rating | Average Price Target | Current Price | Gain Potential | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | C$129.81 | C$116.88 | +10.93% | 11 |
| OUTPERFORM | C$129.7 | C$115.3 | +12.50% | 15 |
| Moderate Buy | C$131.30 | C$114.91 | +14.26% | 14 |
Analysts’ Outlook Summary
Analysts have a generally positive outlook for Bank of Montreal (BMO). The stock is rated as a Moderate Buy or OUTPERFORM by most analysts, indicating that they expect the stock to perform better than the market or its peers over the next year.
Federal Realty Investment Trust (FRT)
Overview
Federal Realty Investment Trust is a premier REIT managing over 2,400 leases in shopping centers and retail properties, focusing on high-quality urban and suburban markets.
Investment Appeal
FRT boasts consistent earnings growth and a dividend yield of 2.6%. The recent pullback and subsequent reversal present a lucrative entry point. Proprietary buy signals further bolster the case for FRT, projecting a total annual return exceeding 16%. This REIT’s resilience and potential for substantial returns make it a compelling choice for investors seeking reliable income and growth amidst economic uncertainties.
Federal Realty Investment Trust (FRT): Strong Buy Signal and High Dividend Yield
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Strong Buy | $112.93 | $106.31 | 6.23% | 8 |
Summary of Analyst Outlook
Analysts have a strong favorable outlook for Federal Realty Investment Trust (FRT), as evident from the high number of Strong Buy ratings and the significant potential gain in stock prices. The average price target suggests a 6.23% increase from the current stock price. This optimistic view is consistent across various sources, including TipRanks and Nasdaq analyst research, which highlight the consensus among analysts in the past three months.
Gilead Sciences (GILD)
Overview
Gilead Sciences is renowned for its groundbreaking treatments for Hepatitis C and HIV, positioning it as a significant player in the biotech industry.
Investment Appeal
Despite facing setbacks, such as FDA rejections, Gilead Sciences has regained momentum following the European Commission’s approval of its HIV treatment. The stock has delivered a 50% gain since its initial recommendation, and holding onto it for further developments is advisable. With a trading target of $65, protective options strategies are recommended to safeguard gains while capitalizing on future upside potential. GILD‘s resilience and innovative pipeline present a unique investment opportunity.
GILD: On Track for a 11% Gain after Earning FDA and European Approvals
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | $77.55 – $82.59 | $68.49 – $69.96 | 10.85% | 25 |
Summary of Analyst Outlook
The consensus rating for Gilead Sciences Inc. (GILD) is a Moderate Buy, which is based on buy, hold, and sell ratings as per various sources. The average price target for the stock is around $77.55 to $82.59, indicating a potential increase of about 10.85% compared to the current price. Analysts are optimistic about the stock’s performance, although there is a range in the forecasts.
Omnicom Group (OMC)
Overview
Omnicom Group is a global leader in advertising and marketing communications services, boasting steady earnings growth and a reputation for consistent performance.
Investment Appeal
OMC‘s recent breakout from a double-top pattern, coupled with a strong Confirmed Buy Recommendation (CBR) signal, indicates a positive outlook. Projected earnings growth supports a target of $73. This stock exemplifies reliable performance and growth potential, making it a worthy addition to any diversified portfolio. Omnicom’s ability to adapt and thrive in the competitive landscape of global advertising underscores its appeal.
OMC: Tapping Into Global Advertising with Double-Top Breakout Signal
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | $104.39 | $92.27 | 13.12% | 9 |
Summary of Analyst Outlook
Analysts are generally optimistic about Omnicom Group stock. The consensus rating is a Moderate Buy, indicating that most analysts expect the stock to perform better than the market over the next twelve months. The average price target of $104.39 suggests a significant potential gain relative to the current price of $92.27. This expectation is bolstered by the potential upside of 13.12% from the current price.
Pfizer (PFE)
Overview
Pfizer, the world’s largest pharmaceutical company, is renowned for its extensive range of popular drugs and innovative treatments.
Investment Appeal
With a dividend yield of 3.3% and plans to spin off Zoetis, Pfizer remains an attractive investment. The stock’s steady bullish trend since January 2012, reinforced by recent buy signals, supports a 12-month price target of $35. This translates to a potential total return of 24%, making PFE a promising option for investors seeking steady income and growth. Pfizer’s strategic focus on its core business and solid dividend yield provide a balanced opportunity for market-wary investors.
PFE: The 24% Return Awaiting Investors – Don’t Miss Out!
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | $33.83 | $27.83 | 16.98% | 15 |
Summary of Analyst Outlook
- Consensus Rating: The consensus rating from a variety of analysts is a Moderate Buy, indicating generally positive expectations about the stock.
- Average Price Target: The average price target from 15 analysts is $33.83, representing a potential gain of 16.98% from the current price.
- Current Price: The current closing price of Pfizer stock is $27.83.
- Future Performance: The average price target suggests a positive outlook for the stock, with some analysts predicting a high of $53.00 and a low of $27.00.
By focusing on these stocks – AEIS, BMO, FRT, GILD, OMC, and PFE – investors can leverage current market conditions to build a robust and diversified portfolio. Each stock offers unique opportunities for growth and stability, catering to the intelligent investor’s quest for value amidst volatility. Stay tuned, stay smart, and happy investing!
